Pharmacometabolomics and mass spectrometry imaging approach to reveal the neurochemical mechanisms of <i>Polygala tenuifolia</i>

Qian Li; Jinpeng Bai; Yuxue Ma; Yu Sun; Wenbin Zhou; Zhaoying Wang; Zhi Zhou; Zhonghua Wang; Yanhua Chen; Zeper Abliz

doi:10.1016/j.jpha.2024.100973

Volume 14 Issue 7

Jul. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2024 > 14(7): 100973

Qian Li, Jinpeng Bai, Yuxue Ma, Yu Sun, Wenbin Zhou, Zhaoying Wang, Zhi Zhou, Zhonghua Wang, Yanhua Chen, Zeper Abliz. Pharmacometabolomics and mass spectrometry imaging approach to reveal the neurochemical mechanisms of Polygala tenuifolia[J]. Journal of Pharmaceutical Analysis, 2024, 14(7): 100973. doi: 10.1016/j.jpha.2024.100973

Citation:

Qian Li, Jinpeng Bai, Yuxue Ma, Yu Sun, Wenbin Zhou, Zhaoying Wang, Zhi Zhou, Zhonghua Wang, Yanhua Chen, Zeper Abliz. Pharmacometabolomics and mass spectrometry imaging approach to reveal the neurochemical mechanisms of Polygala tenuifolia[J]. Journal of Pharmaceutical Analysis, 2024, 14(7): 100973. doi: 10.1016/j.jpha.2024.100973

Citation:

Qian Li, Jinpeng Bai, Yuxue Ma, Yu Sun, Wenbin Zhou, Zhaoying Wang, Zhi Zhou, Zhonghua Wang, Yanhua Chen, Zeper Abliz. Pharmacometabolomics and mass spectrometry imaging approach to reveal the neurochemical mechanisms of Polygala tenuifolia[J]. Journal of Pharmaceutical Analysis, 2024, 14(7): 100973. doi: 10.1016/j.jpha.2024.100973

PDF( 3285 KB)

Pharmacometabolomics and mass spectrometry imaging approach to reveal the neurochemical mechanisms of Polygala tenuifolia

doi: 10.1016/j.jpha.2024.100973

Qian Li^a,b,
Jinpeng Bai^a,c,
Yuxue Ma^a,b,
Yu Sun^a,c,
Wenbin Zhou^a,b,
Zhaoying Wang^a,c,
Zhi Zhou^a,c,
Zhonghua Wang^a,c,
Yanhua Chen^{a,c
,
,},
Zeper Abliz^{a,b,c,d
,
,}

a. Key Laboratory of Mass Spectrometry Imaging and Metabolomics (National Ethnic Affairs Commission), Minzu University of China, Beijing, 100081, China;
b. Key Laboratory of Ethnomedicine of Ministry of Education, School of Pharmacy, Minzu University of China, Beijing, 100081, China;
c. Center for Imaging and Systems Biology, College of Life and Environmental Sciences, Minzu University of China, Beijing, 100081, China;
d. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100050, China

Funds:

The authors thank the financial support from the National Key R&D Program of China (Grant No: 2022YFC3401003), the National Natural Science Foundation of China (Grant No: 21927808), the National Natural Science Foundation of China (Grant No: 22104160), the National Key Research and Development Program of China (Grant No: 2017YFC1704006), and the Innovation Team of Ethnomedicine of National Ethnic Affairs Commission, China.

Received Date: Dec. 24, 2023
Accepted Date: Mar. 25, 2024
Rev Recd Date: Mar. 02, 2024
Publish Date: Mar. 28, 2024

Abstract

Abstract

Polygala tenuifolia, commonly known as Yuanzhi (YZ) in Chinese, has been shown to possess anti-insomnia properties. However, the material basis and the mechanism underlying its sedative-hypnotic effects remain unclear. Herein, we investigated the active components and neurochemical mechanism of YZ extracts using liquid chromatography tandem mass spectrometry (LC-MS/MS)-based pharmacometabolomics and mass spectrometry imaging (MSI)-based spatial resolved metabolomics. According to the results, 17 prototypes out of 101 ingredients in the YZ extract were detected in both the plasma and brain, which might be the major components contributing to the sedative-hypnotic effects. Network pharmacology analysis revealed that these prototypes may exert their effects through neuroactive ligand-receptor interaction, serotonergic synapse, dopaminergic synapse, and dopaminergic synapse, among other pathways. LC-MS/MS-based targeted metabolomics and Western blot (WB) revealed that tryptophan-serotonin-melatonin (Trp-5-HT-Mel) and tyrosine-norepinephrine-adrenaline (Tyr-Ne-Ad) are the key regulated pathways. Dopa decarboxylase (DDC) upregulation and phenylethanolamine N-methyltransferase (PNMT) downregulation further confirmed these pathways. Furthermore, MSI-based spatially resolved metabolomics revealed notable alterations in 5-HT in the pineal gland (PG), and Ad in the brainstem, including the middle brain (MB), pons (PN), and hypothalamus (HY). In summary, this study illustrates the efficacy of an integrated multidimensional metabolomics approach in unraveling the sedative-hypnotic effects and neurochemical mechanisms of a Chinese herbal medicine, YZ.
- Polygala tenuifolia,
- Pharmaceutical metabolomics,
- Spatially resolved metabolome,
- Sedative-hypnotic,
- Neurochemical mechanisms

FullText(HTML)

References(56)

References

[1]	D. Riemann, F. Benz, R.J. Dressle, et al., Insomnia disorder: State of the science and challenges for the future, J.Sleep Res. 31 (2022), e13604.
[2]	X. Huang, H. Jiang, J. Pei, et al., Study on the potential mechanism, therapeutic drugs and prescriptions of insomnia based on bioinformatics and molecular docking, Comput. Biol. Med. 149 (2022), 106001.
[3]	I. Bjoroey, V.A. Joergensen, S. Pallesen, et al., The prevalence of insomnia subtypes in relation to demographic characteristics, anxiety, depression, alcohol consumption and use of hypnotics, Front. Psychol. 11 (2020), 527.
[4]	D.J. Buysse, J. Angst, A. Gamma, et al., Prevalence, course, and comorbidity of insomnia and depression in young adults, Sleep 31 (2008) 473-480.
[5]	L. Zhang, L. Cheng, T. Wang, et al., Chain mediating effect of insomnia, depression, and anxiety on the relationship between nightmares and cognitive deficits in adolescents, J. Affect. Disord. 322 (2023) 2-8.
[6]	K.A. Wafford, B. Ebert, Emerging anti-insomnia drugs: Tackling sleeplessness and the quality of wake time, Nat. Rev. Drug Discov. 7 (2008) 530-540.
[7]	A.N. Edinoff, N. Wu, Y.T. Ghaffar, et al., Zolpidem: Efficacy and side effects for insomnia, Health Psychol. Res. 9 (2021), 24927.
[8]	C.P. Commission, Pharmacopoeia of the Peoples Republic of China, China Medical Science Press, Beijing, 2020, pp. 163-166.
[9]	L. Zhang, Y. Yong, L. Deng, et al., Therapeutic potential of Polygala saponins in neurological diseases, Phytomedicine 108 (2023), 154483.
[10]	Y. Yao, M. Jia, J. Wu, et al., Anxiolytic and sedative-hypnotic activities of polygalasaponins from Polygala tenuifolia in mice, Pharm. Biol. 48 (2010) 801-807.
[11]	Q. Cao, Y. Jiang, S. Cui, et al., Tenuifolin, a saponin derived from Radix Polygalae, exhibits sleep-enhancing effects in mice, Phytomedicine 23 (2016) 1797-1805.
[12]	R. Jesky, H. Chen, The neuritogenic and neuroprotective potential of senegenin against Aβ-induced neurotoxicity in PC 12 cells, BMC Complement. Altern. Med. 16 (2016), 26.
[13]	M.A. Lacaille-Dubois, C. Delaude, A.C. Mitaine-Offer, A review on the phytopharmacological studies of the genus Polygala, J. Ethnopharmacol. 249 (2020), 112417.
[14]	Z. Jin, N. Gao, J. Zhang, et al., The discovery of Yuanzhi-1, a triterpenoid saponin derived from the traditional Chinese medicine, has antidepressant-like activity, Prog. Neuropsychopharmacol. Biol. Psychiatry 53 (2014) 9-14.
[15]	T. Li, Z. Zhou, K. Zhang, et al., Direct infusion-tandem mass spectrometry combining with data mining strategies enables rapid chemome characterization of medicinal plants: A case study of Polygala tenuifolia, J. Pharm. Biomed. Anal. 204 (2021), 114281.
[16]	L. Liu, W.-H. Feng, X.-Q. Liu, et al., Research progress on Polygalae Radix, Zhongguo Zhong Yao Za Zhi 46 (2021) 5744-5759.
[17]	S. Grover, K.S. Kasudhan, N. Murali, et al., Pharmacometabolomics-guided clozapine therapy in treatment resistant schizophrenia: Preliminary exploration of future too near, Asian J. Psychiatry 67 (2022), 102939.
[18]	T. Wang, J. Liu, X. Luo, et al., Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds, Pharmacol. Ther. 224 (2021), 107824.
[19]	Y. Chen, Q. Pu, F. Yu, et al., Comprehensive quantitative method for neurotransmitters to study the activity of a sedative-hypnotic candidate using microdialysis and LC × LC-MS/MS, Talanta 245 (2022), 123418.
[20]	D. Shao, X. Liu, J. Wu, et al., Identification of the active compounds and functional mechanisms of Jinshui Huanxian formula in pulmonary fibrosis by integrating serum pharmacochemistry with network pharmacology, Phytomedicine 102 (2022), 154177.
[21]	J. Wei, Y. Yu, Y. Zhang, et al., Integrated serum pharmacochemistry and network pharmacology approach to explore the effective components and potential mechanisms of menispermi rhizoma against myocardial ischemia, Front. Chem. 10 (2022), 869972.
[22]	J.M. Moon, N. Thapliyal, K.K. Hussain, et al., Conducting polymer-based electrochemical biosensors for neurotransmitters: A review, Biosens. Bioelectron. 102 (2018) 540-552.
[23]	R.I. Teleanu, A.G. Niculescu, E. Roza, et al., Neurotransmitters-key factors in neurological and neurodegenerative disorders of the central nervous system, Int. J. Mol. Sci. 23 (2022), 5954.
[24]	J. He, C. Sun, T. Li, et al., A sensitive and wide coverage ambient mass spectrometry imaging method for functional metabolites based molecular histology, Adv. Sci. (Weinh.) 5 (2018), 1800250.
[25]	X. Pang, S. Gao, M. Ga, et al., Mapping metabolic networks in the brain by ambient mass spectrometry imaging and metabolomics, Anal. Chem. 93 (2021) 6746-6754.
[26]	D. Liu, J. Huang, S. Gao, et al., A temporo-spatial pharmacometabolomics method to characterize pharmacokinetics and pharmacodynamics in the brain microregions by using ambient mass spectrometry imaging, Acta Pharm. Sin. B 12 (2022) 3341-3353.
[27]	B. Jin, X. Pang, Q. Zang, et al., Spatiotemporally resolved metabolomics and isotope tracing reveal CNS drug targets, Acta Pharm. Sin. B 13 (2023) 1699-1710.
[28]	L. Chen, D. Xu, J. Kong, et al., Separation and identification of the hypnotic active ingredients of Polygala tenuifolia Willd, Food Mach. 34 (2018) 119-122, 182.
[29]	Y. Djeridane, B. Lemmer, Y. Touitou, Diazepam affects both level and amplitude of rat locomotor activity rhythm but has no effect on core body temperature, Chronobiol. Int. 22 (2005) 975-985.
[30]	L. Lin, L. Yan, H. Zhang, et al., Simultaneous analysis of polygala acid, senegenin and 3,6'-disinapoylsucrose in rat plasma by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetic study after oral administration, Biomed. Chromatogr. 28 (2014) 594-600.
[31]	X. Zhao, B. Xu, P. Wu, et al., UHPLC-MS/MS method for pharmacokinetic and bioavailability determination of five bioactive components in raw and various processed products of Polygala tenuifolia in rat plasma, Pharm. Biol. 58 (2020) 969-978.
[32]	Z. Zhou, Y. Chen, J. He, et al., Systematic evaluation of serum and plasma collection on the endogenous metabolome, Bioanalysis 9 (2017) 239-250.
[33]	X. Ren, G. Wang, X. Zhang, et al., Sedative and hypnotic effects and transcriptome analysis of Polygala tenuifolia in aged insomnia rats, Chin. J. Integr. Med. 26 (2020) 434-441.
[34]	S.K. Wood, R.J. Valentino, The brain norepinephrine system, stress and cardiovascular vulnerability, Neurosci. Biobehav. Rev. 74 (2017) 393-400.
[35]	A. Tavares, D.E. Handy, N.N. Bogdanova, et al., Localization of alpha 2A- and alpha 2B-adrenergic receptor subtypes in brain, Hypertension 27 (1996) 449-455.
[36]	W. Peng, Z. Wu, K. Song, et al., Regulation of sleep homeostasis mediator adenosine by basal forebrain glutamatergic neurons, Science 369 (2020), eabb0556.
[37]	T. Porkka-Heiskanen, L. Alanko, A. Kalinchuk, et al., Adenosine and sleep, Sleep Med. Rev. 6 (2002) 321-332.
[38]	X. Dai, E. Zhou, W. Yang, et al., Molecular resolution of a behavioral paradox: Sleep and arousal are regulated by distinct acetylcholine receptors in different neuronal types in Drosophila, Sleep 44 (2021), zsab017.
[39]	F. Weber, Y. Dan, Circuit-based interrogation of sleep control, Nature 538 (2016) 51-59.
[40]	B. Platt, G. Riedel, The cholinergic system, EEG and sleep, Behav. Brain Res. 221 (2011) 499-504.
[41]	M.M. Thakkar, Histamine in the regulation of wakefulness, Sleep Med. Rev. 15 (2011) 65-74.
[42]	M. Shariatgorji, A. Nilsson, E. Fridjonsdottir, et al., Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging, Nat. Methods 16 (2019) 1021-1028.
[43]	R. Shariatgorji, A. Nilsson, E. Fridjonsdottir, et al., Spatial visualization of comprehensive brain neurotransmitter systems and neuroactive substances by selective in situ chemical derivatization mass spectrometry imaging, Nat. Protoc. 16 (2021) 3298-3321.
[44]	Y.-H. Wu, D.F. Swaab, The human pineal gland and melatonin in aging and Alzheimer’s disease, J. Pineal Res. 38 (2005) 145-152.
[45]	A. Ni, C. Ernst, Evidence that substantia nigra pars compacta dopaminergic neurons are selectively vulnerable to oxidative stress because they are highly metabolically active, Front. Cell. Neurosci. 16 (2022), 826193.
[46]	Y. Si, L. Wang, J. Lan, et al., Lilium davidii extract alleviates p-chlorophenylalanine-induced insomnia in rats through modification of the hypothalamic-related neurotransmitters, melatonin and homeostasis of the hypothalamic-pituitary-adrenal axis, Pharm. Biol. 58 (2020) 915-924.
[47]	Y. Xu, L. Ma, F. Liu, et al., Lavender essential oil fractions alleviate sleep disorders induced by the combination of anxiety and caffeine in mice, J. Ethnopharmacol. 302 (2023), 115868.
[48]	H. Xu, Z. Wang, L. Zhu, et al., Targeted neurotransmitters profiling identifies metabolic signatures in rat brain by LC-MS/MS: Application in insomnia, depression and Alzheimer’s disease, Molecules 23 (2018), 2375.
[49]	E. Costa, A. Guidotti, C.C. Mao, et al., New concepts on the mechanism of action of benzodiazepines, Life Sci. 17 (1975) 167-185.
[50]	G. Spadoni, A. Bedini, S. Rivara, et al., Melatonin receptor agonists: New options for insomnia and depression treatment, CNS Neurosci. Ther. 17 (2011) 733-741.
[51]	A.D. Krystal, E. Richelson, T. Roth, Review of the histamine system and the clinical effects of H1 antagonists: Basis for a new model for understanding the effects of insomnia medications, Sleep Med. Rev. 17 (2013) 263-272.
[52]	W.A. Santos Moraes, P.R. Burke, P.L. Coutinho, et al., Sedative antidepressants and insomnia, Braz. J. Psychiatry 33 (2011) 91-95.
[53]	C. Gudex, Adverse effects of benzodiazepines, Soc. Sci. Med. 33 (1991) 587-596.
[54]	K.Y. Shin, B.Y. Won, H.J. Ha, et al., Preclinical safety of the root extract of Polygala tenuifolia willdenow in sprague-dawley rats and beagle dogs, Evid. Based Complementary Altern. Med. 2014 (2014), 570134.
[55]	N.A. DeMartinis, A. Winokur, Effects of psychiatric medications on sleep and sleep disorders, CNS Neurol. Disord. Drug Targets 6 (2007) 17-29.
[56]	A. Winokur, K.A. Gary, S. Rodner, et al., Depression, sleep physiology, and antidepressant drugs, Depress. Anxiety 14 (2001) 19-28.